Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

Gilead promotes Andrew Dickinson to CFO, increased M&A expected

Gilead promotes Andrew Dickinson to CFO, increased M&A expected

Gilead acquired the rights to Kite’s CAR-T therapy Yescarta (axicabtagene ciloleucel) for lymphoma in that deal – however, the drug continues to fall short of analyst expectations, bringing in $264m ... The new CEO is focused on steering Gilead away

Latest news

  • SMC approves Yescarta and Keytruda, rejects Perjeta SMC approves Yescarta and Keytruda, rejects Perjeta

    Last year, Gilead agreed a market access deal with NHS England for its groundbreaking CAR-T therapy Yescarta (axicabtagene ciloleucel), with the approval in Scotland extending the drug’s reach. ... The SMC has approved Yescarta for the

  • Gilead poaches Genentech-exec Merdad Parsey for its new CMO Gilead poaches Genentech-exec Merdad Parsey for its new CMO

    The Genentech exec will be no stranger to immuno-oncology, which is of special interest for Gilead and is a therapy area that the company has recently turned its focus on. ... Although the company’s first CAR-T therapy Yescarta (axicabtagene ciloleucel)

  • Gracell reports impressive data with one-day CAR-T for leukaemia Gracell reports impressive data with one-day CAR-T for leukaemia

    The testing phase still applies with  Gracell’s approach of course, but that means the CAR-T therapy can be prepared in as little as eight days, whereas Kymriah needs a ... The biotech thinks that its express approach to production will also reduce

  • Novartis’ CAR-T Kymriah scores SMC approval Novartis’ CAR-T Kymriah scores SMC approval

    The SMC approved the CAR-T therapy for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who have not responded to two or more prior ... Gilead faced an  initial hurdle when initially NICE rejected the use of its

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    CAR-T cell therapies, the most clinically established form of ACT, can recognise only the specific antigens on the surface of cancer cells. ... The deal adds to Celgene existing presence in cell therapy - it is working with  Bluebird Bio, on CAR-T

More from news
Approximately 8 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... In the case of a personalised therapy like CAR-T, the cost of the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH

  • Deal Watch October 2018

    radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • Precision paediatrics: Treating patients with CAR-T

    Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma...
WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....

Quick links

Infographics

Multimedia